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Background: Peroxisome proliferator-activated receptor α (PPARα), a central regulator of fatty acid catabolism, has
recently been shown to be a transcriptional regulator of the gene encoding the carnitine transporter novel organic
cation transporter 2 (OCTN2) in cattle. Whether PPARβ/δ, another PPAR subtype, which has partially overlapping
functions as PPARα and is known to share a large set of common target genes with PPARα, also regulates OCTN2
and carnitine transport in cattle is currently unknown. To close this gap of knowledge, we studied the effect of
the PPARβ/δ activator GW0742 on mRNA and protein levels of OCTN2 and carnitine uptake in the presence and
absence of the PPARβ/δ antagonist GSK3787 in the bovine Madin-Darby bovine kidney (MDBK) cell line.
Findings: Treatment of MDBK cells with GW0742 caused a strong increase in the mRNA level of the known bovine
PPARβ/δ target gene CPT1A in MDBK cells indicating activation of PPARβ/δ. The mRNA and protein level of OCTN2
was clearly elevated in MDBK cells treated with GW0742, but the stimulatory effect of GW0742 on mRNA and
protein level of OCTN2 was completely blocked by GSK3787. In addition, GW0742 increased Na+-dependent
carnitine uptake, which is mediated by OCTN2, into MDBK cells, whereas treatment of cells with the PPARβ/δ
antagonist completely abolished the stimulatory effect of GW0742 on carnitine uptake.
Conclusions: The present study shows for the first time that gene expression of the carnitine transporter OCTN2
and carnitine transport are regulated by PPARβ/δ in bovine cells. These novel findings extend the knowledge about
the molecular regulation of the OCTN2 gene and carnitine transport in cattle and indicate that regulation of OCTN2
gene expression and carnitine transport is not restricted to the PPARα subtype.
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The peroxisome proliferator-activated receptors (PPARs)
are ligand-activated transcription factors which play im-
portant roles in many metabolic and regulatory pathways
through regulating the expression of a large set of target
genes [1]. The ligands of PPARs include fatty acids and
fatty acid derivatives and are therefore designated as
transcriptional sensors of fatty acids [2]. In addition, syn-
thetic compounds like the fibrate class of lipid lowering
drugs or the insulin-sensitizing thiazolidinediones are
well documented ligands of PPARs. From the PPARs,
three different subtypes exist which have isotype-specific* Correspondence: klaus.eder@ernaehrung.uni-giessen.de
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unless otherwise stated.but also partially overlapping functions. For instance, both,
the PPARα and the PPARβ/δ subtype are central regulators
of fatty acid catabolism since both subtypes control the ex-
pression of genes encoding proteins involved in cellular
fatty acid uptake, intracellular fatty acid transport, mito-
chondrial fatty acid uptake, and mitochondrial and
peroxisomal fatty acid oxidation [1,3,4]. Recent studies con-
vincingly demonstrated that PPARα is also a key regulator
of genes involved in carnitine transport like novel organic
cation transporter 2 (OCTN2) and carnitine synthesis like
γ-butyrobetain dioxygenase (BBD) in many species includ-
ing dairy cattle [5-8]. Activation of PPARα in dairy cattle
occurs physiologically during early lactation due to ex-
tensive mobilization and release of fatty acids from adipose
tissues which are taken up into the liver and non-hepatic
tissues and bind to and activate PPARα [9,10]. The abovetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pression provides a plausible explanation for the recent
finding that OCTN2 and BBD in the liver are strongly up-
regulated during early lactation in high-producing dairy
cows [11]. However, whether PPARβ/δ also regulates genes
involved in carnitine homeostasis in cattle is currently un-
known. PPARα and PPARβ/δ share a large set of common
target genes involved in fatty acid catabolism. In addition,
carnitine transport and synthesis are intrinsically linked to
fatty acid catabolism, because fatty acid transport into the
mitochondrial matrix is carnitine-dependent [12]. Thus, we
hypothesized that PPARβ/δ also regulates genes involved in
carnitine homeostasis in cattle. To verify our hypothesis we
studied the effect of the PPARβ/δ activator GW0742 on
mRNA and protein levels of OCTN2 and carnitine trans-
port in a bovine kidney cell line. Using this cell line we have
very recently shown that OCTN2 gene expression and car-
nitine transport are stimulated by a PPARα agonist [13].
However, kidney cells are also of relevance to study the ef-
fect of PPARβ/δ agonists in this regard because PPARβ/δ is
known to be highly expressed in the kidney and OCTN2-
mediated carnitine transport represents the transport
mechanism for tubular reabsorption of carnitine in the kid-
ney and is therefore fundamental for maintaining normal
carnitine levels in serum [14]. We did not consider the ef-
fect of GW0742 on genes involved in carnitine synthesis in
this cell line, because the kidney, unlike the liver, is not cap-
able of synthesizing carnitine due to the lack of BBD.
Madin-Darby bovine kidney (MDBK) cells obtained
from Cell Lines Service (Eppelheim, Germany) were cul-
tivated in HyClone Minimum Essential Media/Earle’s
Balanced Salt Solution (MEM/EBSS) medium supple-
mented with 10% FBS and 0.05 mg/mL gentamicin (all
from Invitrogen, Karlsruhe, Germany) at 37°C in a hu-
midified atmosphere of 95% air and 5% CO2 [13]. After
reaching 80% confluence, MDBK cells were treated with
1 μM of the PPARβ/δ selective agonist GW0742 (Sigma-
Aldrich, Steinheim, Germany) [dissolved in dimethylsulf-
oxide (DMSO); both from Sigma-Aldrich, Steinheim,
Germany] in MEM/EBSS medium without FBS but
5 mg/L bovine insulin (Sigma-Aldrich, Steinheim,
Germany) for 24 h. The incubation concentration of
GW0742 was chosen based on published literature [15],
in which treatment with 1 μM resulted in strong activa-
tion of PPARβ/δ. The incubation time was selected
based on results from initial time course experiments
(4 h, 24 h) demonstrating that the effect of GW0742 was
stronger at 24 h (Figure 1A). Cells treated with vehicle
alone (DMSO) were used as control. Incubation media
of control cells contained the same vehicle concentration
of 0.1% (v/v). For experiments using a PPARβ/δ inhibi-
tor, cells were co-treated with 10 μM of the PPARβ/δ se-
lective antagonist GSK3787 (Sigma-Aldrich) for 24 h.
The incubation time and incubation concentration ofGSK3787 was chosen also based on results from initial
titration and time course experiments (concentration: 1
and 10 μM; time: 4 h, 24 h) demonstrating that inhib-
ition of the agonist effect by GSK3787 was strongest at
10 μM and 24 h (Figure 1B). Following incubation,
media was aspirated, the cell layer was washed once with
phosphate-buffered saline, and plates including the at-
tached cells were immediately stored at −80°C. All incu-
bations were run in triplicate and each experiment was
repeated three times. The mRNA levels of genes of
interest (reference and target genes) in MDBK cells were
determined by means of qPCR. Prior to qPCR, RNA
from cells was isolated by adding TrizolTM reagent
(Invitrogen, Karlsruhe, Germany) directly into the wells,
and pipetting the lysed cells up and down 2–3 times.
cDNA was synthesized in less than a week after RNA ex-
traction from 1.2 μg of total RNA using 100 pmol dT18
primer (Eurofins MWG Operon, Ebersberg, Germany),
1.25 μL 10 mmol/L dNTP mix (GeneCraft, Lüdinghau-
sen, Germany), 5 μL buffer (Fermentas, St. Leon-Rot,
Deutschland), and 60 units M-MuLV Reverse Tran-
scriptase (MBI Fermentas, St. Leon-Rot, Germany) at
42°C for 60 min, and a final inactivating step at 70°C for
10 min in a Thermal Cycler. qPCR was performed using
2 μL cDNA combined with 18 μL of a mixture com-
posed of 10 μL KAPA SYBR FAST qPCR Universal Mas-
termix (Peqlab, Erlangen, Germany), 0.4 μL each of
10 μM forward and reverse primers and 7.2 μL DNase/
RNase free water in 0.1 mL tubes (Ltf Labortechnik,
Wasserburg, Germany). Ct-values of target genes and
reference genes were obtained using Rotorgene Software
5.0 (Corbett Research). For determination of relative ex-
pression levels relative quantities were calculated using
GeNorm normalization factor according to Vandesom-
pele et al. [16]. The normalization factor was calculated
as the geometric mean of expression data of the three
most stable (ACTB, ATP5B, SDHA) out of five tested po-
tential reference genes (ACTB, ATP5B, PPIA, RPS9,
SDHA). Primer characteristics and qPCR performance
data for the reference genes and target genes have been
published recently [9]. Means and SD were calculated
from normalized expression data for samples of the
same treatment group. The mean of the vehicle (DMSO)
control group was set to 1 and mean and SD of the
GW0742 and GW0742 + GSK3787 groups were scaled
proportionally. For immunoblot analysis, MDBK cells
were lysed with RIPA lysis buffer (50 mM Tris, pH 7.5;
150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1%
SDS, 1% sodium deoxycholate) containing protease in-
hibitors (Sigma-Aldrich). Following determination of
protein concentration of the cell lysates, 25 μg protein
from the cell lysates were separated on a 10% SDS-
PAGE, and proteins were transferred to a nitrocellulose
membrane. Subsequently, membranes were blocked
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Figure 1 Effect of incubation time and effect of concentration of PPARβ/δ antagonist on relative mRNA level of OCTN2 in MDBK cells.
A, Effect of treatment with 1 μM of PPARβ/δ agonist GW0742 for 4 and 24 h on mRNA level of OCTN2. B, Effect of treatment with 1 and 10 μM
of PPARβ/δ selective antagonist GSK3787 for 4 and 24 h on mRNA level of OCTN2. Bars represent means ± SD of three independent experiments
and are expressed as fold of DMSO-treated control cells.
Zhou et al. Acta Veterinaria Scandinavica 2014, 56:21 Page 3 of 5
http://www.actavetscand.com/content/56/1/21overnight at 4°C in blocking solution (5% non-fat dried
milk powder), and then incubated with antibodies
against OCTN2 (polyclonal anti-OCTN2 antibody; dilu-
tion 1:500; Abcam, Cambridge, UK) and β-actin (mono-
clonal anti-β-actin; dilution 1:500, Abcam, Cambridge,
UK) overnight at 4°C and for 2 h at RT, respectively. Fol-
lowing a washing step, the membranes were incubated
with a horseradish peroxidase conjugated secondary
monoclonal anti-mouse-IgG antibody (1:5000, Jackson
Immuno Research, Suffolk, UK) for 1 h at room
temperature. Finally, the blots were developed by using
the AmershamTM ECL Plus Western Blotting Detection
System (GE Healthcare, Munich, Germany) and detected
by a chemiluminescence imager (Syngene, Cambridge,
UK). The signal intensities of specific bands were quanti-
fied using GeneTools software (Syngene, Cambridge, UK).
Carnitine uptake experiments in MDBK cells using
methyl-L-[3H]-carnitine (80 mCi/mmol; American Radi-
olabeled Chemicals, St. Louis, USA) were performed as
described recently in detail [13]. To study the Na+ de-
pendence of carnitine uptake, the incubation buffer con-
tained either 0, 25 or 125 mM NaCl and 4.8 mM KCl,
5.6 mM D-glucose, 1.2 mM CaCl2, 1.2 mM KH2PO4,
1.2 mM MgSO4, and 5 mM HEPES. Radioactivity in cell
lysates determined by scintillation counting (Perkin Elmer
Liquid Scintillation Analyzer Tri-Carb 2900TR, Rodgau,
Germany) was related to protein content of cell lysates as
determined by the bicinchoninic acid protein assay with
BSA as standard. Carnitine uptake is expressed as the
amount of L-[3H]-carnitine taken up per mg cell protein
within 30 min. Statistical evaluation of treatment effects
was carried out by one-way ANOVA and Duncan’s mul-
tiple range test.
In the first step, we investigated whether treatment of
MDBK cells with the PPARβ/δ agonist GW0742 (1 μM)
causes activation of PPARβ/δ. Activation of PPARβ/δ wasevidenced by strongly increased mRNA levels of the known
bovine PPARβ/δ target gene CPT1A in MDBK cells treated
with GW0742 (P < 0.05; Figure 2A). The mRNA level of
PPARβ/δ was slightly elevated by treatment with GW0742
(P < 0.05; Figure 2A). Next, we studied the effect of
GW0742 on the mRNA level of OCTN2 in MDBK cells. As
shown in Figure 2B, the mRNA level of OCTN2 was clearly
elevated in MDBK cells treated with GW0742 (P < 0.05) in-
dicating that bovine OCTN2 gene transcription is regulated
by PPARβ/δ. In addition, induction of the OCTN2 gene by
GW0742 in MDBK cells was also observed at the protein
level (P < 0.05; Figure 2C). To further confirm the PPARβ/δ
dependence of this effect, we studied the effect of GW0742
in the presence of GSK3787 (10 μM) on OCTN2 gene ex-
pression. GSK3787 is a newly identified PPARβ/δ antagon-
ist that can irreversibly attenuate the activity of PPARβ/δ by
forming a covalent bond with a cysteine residue in the lig-
and binding domain of PPARβ/δ [17]. As illustrated in
Figure 2D and E, the stimulatory effect of GW0742 on
mRNA and protein levels of OCTN2 in MDBK cells was
completely blocked by the PPARβ/δ antagonist indicating
that OCTN2 gene expression is regulated by PPARβ/δ in
bovine kidney cells. In a further step, we studied whether
up-regulation of OCTN2 by GW0742 leads to an increased
carnitine uptake. For this, we determined the uptake of
methyl-L-[3H]-carnitine into MDBK cells incubated with or
without GW0742 at different NaCl concentrations in the
incubation medium. As shown in Figure 2F, GW0742
increased carnitine uptake into MDBK cells at a NaCl
concentration of 125 mM in the incubation media (P <
0.05) but not at 0 and 25 mM NaCl. This indicated that
the PPARβ/δ agonist stimulates specifically the OCTN2-
mediated carnitine uptake which is known to be sodium-
dependent [18]. Finally, we provided clear evidence for the
PPARβ/δ dependence of the GW0742-induced increase of
carnitine uptake in showing that treatment of MDBK cells
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Figure 2 The carnitine transporter OCTN2 and carnitine uptake in MDBK cells is regulated by PPARβ/δ. A, Effect of treatment with 1 μM
of GW0742 for 24 h on mRNA levels of CPT1A and PPARD. B-E, Effect of treatment with 1 μM of GW0742 for 24 h in the absence (B, C) and
presence (D, E) of PPARβ/δ selective antagonist GSK3787 (10 μM) on relative mRNA (B, D) and protein levels (C and E) of OCTN2. A, B and D,
Bars represent means ± SD of three independent experiments and are expressed as fold of DMSO-treated control cells. C and E, Bars represent
data from densitometric analysis and are means ± SD of three independent experiments. Immunoblots specific to OCTN2 and β-Actin as internal
control are shown for one independent experiment; immunoblots for the other experiments revealed similar results. Data represent means ± SD
of three independent experiments and are expressed as fold of DMSO-treated control cells. *Different from DMSO-treated control, P < 0.05. F and
G, Effect of treatment with 1 μM of GW0742 on uptake of L-[3H]-carnitine (10 nM, specific radioactivity 80 Ci/mmol). F, Uptake of L-[3H]-carnitine
by MDBK cells treated for 24 h with either GW0742 or DMSO (control) at different Na+ concentrations (0, 25 and 125 mM NaCl) was studied over
30 min. G, Uptake of L-[3H]-carnitine by MDBK cells treated for 24 h with either GW0742, GW0742 together with GSK3787 (10 mM) or DMSO
(control) at 125 mM NaCl was studied over 30 min. Data represent means ± SD of three independent experiments each performed in triplicate. a,b,cData
with different superscript letters differ, P < 0.05. *Different from DMSO-treated control, P < 0.05.
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the stimulatory effect of GW0742 on carnitine up-
take (Figure 2G). In summary, these novel findings
extend the knowledge about the molecular regulation
of the OCTN2 gene and carnitine transport which
have been convincingly demonstrated to be regulated
by PPARα in cattle but also in several other species
[6]. The fact that OCTN2 gene expression and carnitine
transport are obviously regulated by both, PPARα and
PPARβ/δ, is not surprising given that these two PPAR
subtypes have partially overlapping functions. Namely,both PPAR subtypes play important roles in the regula-
tion of mitochondrial fatty acid oxidation, which is
dependent on the presence of carnitine, and therefore
share a large set of common target genes involved in
fatty acid oxidation [15]. Thus, our recent observation
in high-producing dairy cows that OCTN2 is strongly
up-regulated in the liver during early lactation [9]
might be mediated by the activation of both PPAR sub-
types because the fatty acids released from adipose tis-
sue during this state are ligands and activators of both
PPAR subtypes.
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The present study shows for the first time that gene ex-
pression of the carnitine transporter OCTN2 and carni-
tine transport are regulated not only by PPARα but also
by PPARβ/δ in bovine cells.
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